| protein
| SH3 domain of YES tyrosine kinase and SHE domain of YES oncoprotein |
|
interacting with WBP2  |
|
interacts with SMAD7 thereby influencing TGF-beta signaling |
|
interacting with PRGP2 |
|
binding to WBP1 |
|
interacts with TEAD4 mainly through the two short helices |
|
interacting with TJP2 (TJP2 uses its first PDZ domain to form a complex with YAP1) |
|
AXL is a key downstream target that drives YAP1-dependent oncogenic functions |
|
AMOTL1 and AMOTL2, are YAP1-associated proteins |
|
AMOT interacting with YAP1 and TAZ (YAP1 and TAZ inhibition by AMOT-mediated tight junction localization) |
|
the most common interaction partner of YAP1 in keratinocytes corresponded to CTNNA1, an important tumor suppressor in stratified epithelia |
|
FAT4 mediates its action via the Hippo pathway mediator YAP1 |
|
AMOTL1 inhibits pro-apoptotic function of YAP1, whereas TJP2 enhances it |
|
YAP1 stimulation of cardiomyocyte proliferation requires its interaction with TEAD(1-4) |
|
YAP1 protein regulates vascular smooth muscle cell phenotypic switch by interaction with MYOCD |
|
KLF5 could be an important transcription factor partner for YAP1 and may contribute to the Hippo pathway |
|
through its TEAD-interaction domain, YAP1 enhances multiple processes known to be important for tumor progression and metastasis, including cellular proliferation, transformation, migration, and invasion |
|
PTPN14 interacts with yes-associated protein 1 (YAP1), a member of the hippo signaling pathway (PTPN14 acts to suppress cell proliferation by promoting cell density-dependent cytoplasmic translocation of YAP1) |
|
YAP1 expression is required for the tumorigenicity of CTNNB1 active cells |
|
AMOT promotes the ubiquitination of YAP1 by ITCH and prevents ITCH from binding to large tumor suppressor 1 |
|
YAP1 binding to dendrin is a prosurvival mechanism |
|
GABPA is an activator of YAP1 gene expression and a potential therapeutic target for cancers driven by YAP1 |
|
regulation of NAIP by TEAD1/YAP1 is at the transcriptional level |
|
AMOT acts as a YAP1 cofactor, preventing YAP1 phosphorylation and augmenting its activity toward a specific set of genes that facilitate tumorigenesis |
|
AJUBA is required for MAPK8-mediated activation of YAP1 and AJUBA contributed to wing regeneration after wounding and to tumor growth |
|
PTPN11 physically interacts with transcriptional coactivators YAP1 and TAZ, targets of the cell-density-sensing Hippo signal |
|
LATS1/LATS2 involved in phosphorylation of AMOT130, which is a key feature that enables it to inhibit YAP1-dependent signaling and cell growth |
|
NEDD4 directly interacts with LATS1, leading to ubiquitination and decreased levels of LATS1 and, thus, increased YAP1 localization in the nucleus |
|
MEN1 binds to YAP1 promoter loci and up-regulates H3K4me3 |
|
negatively regulates YAP1 activity through the LATS family, and inactivation of AJUBA is a novel key mechanism in malignant mesothelioma cell proliferation |
|
VGLL4 is a novel tumor suppressor for lung cancer through negatively regulating the YAP1-TEAD complex formation and thus the Hippo pathway |
|
is a positive regulator of YAP1 and promotes cell growth and cell cycle progression through Cyclin A upregulation |
|
ARHGEF7 is a key component that links the Hippo kinase cassette to YAP1/WWTR1 in response to multiple upstream Hippo pathway activators |
|
actin remodelling factors LIMK2 and TESK1 are key players in the ciliogenesis control network in which YAP1/WWTR1 and directional vesicle trafficking are integral components |
|
MAMDC4 competes with YAP1 for binding to AMOT proteins in subconfluent cells |
|
CRB3 promotes the interaction between YAP1 and the Hippo pathway kinases LATS1/2 at apical cell junctions to induce YAP1 phosphorylation and cytoplasmic retention, which drive cell differentiation |
|
EPS8, a signaling adapter regulating actin dynamics, is a novel partner of CDH5 and is able to modulate YAP1 activity 7) |
|
KDM4A cooperated with ETV1 to increase expression of yes associated protein 1 (YAP1), a Hippo pathway component that itself was associated with prostate tumor aggressiveness |
|
AMOT can interact with YAP1 to either stimulate or inhibit YAP1 activity, playing a potential role in cell proliferation |
|
CIZ1 enhanced the interaction between YAP1 and TEAD1 |
|
CDC42/WASL/stress fibers/YAP1 signal pathway may potentially play an important role in regulating podocyte apoptosis |
|
S100A7 is repressed by YAP1 via the Hippo pathway |
|
RASSF1 limits TGFB1 induced invasion, offering a new framework on how RASSF1 affects YAP1 transcriptional output and elicits its tumor-suppressive function |
|
YAP1 promotes myelin and non-myelin genes transcription while the polarity protein CRB3, localized at the tips of the myelin sheath, activates the Hippo pathway to temper YAP1 activity, therefore allowing for optimal myelin growth |
|
YAP1 activates JAG2 expression in muscle fibers, which in turn regulates the pool of fetal muscle progenitors via NOTCH1 in a non-cell-autonomous manner |
|
acetylation-mediated, VGLL4-dependent switch that regulates TEAD1 stability and YAP1-TEAD1 activity |
|
JMJD1C controls the proliferation of Esophageal cancer (EC) via modulation of H3K9me2 activity, targeting the YAP1 gene expression and functions as a tumor suppressor in EC |
|
nuclear translocation of AMOTL1 is likely accompanied by YAP1 to promote cardiomyocyte proliferation |
|
specific interactions between YAP1 and proteins in the ERK5 pathway, such as MEK kinase 3 (MAP3K3) and MAPK7 |
|
YOD1 stabilizes ITCH and facilitates ITCH-mediated LATS1/2 ubiquitination and degradation, which results in increased YAP1/TAZ level |
|
VGLL4 negatively regulates the TEAD1-YAP1 transcriptional complex and exerts its growth inhibitory control through its evolutionary conserved TDU2 domain at its C-terminus |
|
functions as a transcriptional co-repressor in the Hippo-Yes-associated protein (YAP1) pathway |
|
YAP1 is protective against VSMC apoptosis induced by ER stress through inhibiting CASP8/3 activation mediated in part by upregulation of ANKRD1 |
|
ANKRD1 is a YAP1 target gene that is induced by RASSF1 |
|
YAP1 repression of the WNT3 gene controls hESC differentiation along the cardiac mesoderm lineage |
|
NUP37 interacted with YAP1 and activated YAP1/TEAD1 signaling by enhancing the interaction between YAP1 and TEAD1 |
|
RASSF1 mediates transcription factor selection of YAP1 in stem cells, thereby acting as a functional "switch" between pluripotency and initiation of differentiation 9) |
|
CLDN18 is a regulator of YAP1 activity that serves to restrict organ size, progenitor cell proliferation, and tumorigenesis |
|
ZYX promotes colon cancer tumorigenesis in a mitotic-phosphorylation-dependent manner and through CDK8-mediated YAP1 activation |
|
VGLL4 is an important regulator of CD274 expression, suggesting a central role of VGLL4 and YAP1 in the regulation of tumor immunity |
|
YAP1 is a direct target of METTL14 in acute kidney injury (AKI) progression |
|
YAP1 is downstream of ARHGAP18 in mature endothelial cells and this pathway is involved in the athero-protective alignment of endothelial cells under laminar shear stress |
